Q3 Earnings Estimate for Penumbra Issued By Leerink Partnrs

Penumbra, Inc. (NYSE:PEN) – Analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Penumbra in a report released on Tuesday, February 18th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings per share of $0.98 for the quarter, down from their previous estimate of $1.09. The consensus estimate for Penumbra’s current full-year earnings is $3.86 per share. Leerink Partnrs also issued estimates for Penumbra’s Q4 2025 earnings at $1.11 EPS, FY2027 earnings at $6.86 EPS, FY2028 earnings at $7.92 EPS and FY2029 earnings at $8.96 EPS.

Penumbra (NYSE:PEN) last announced its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.09. The business had revenue of $315.52 million for the quarter, compared to analysts’ expectations of $311.63 million. Penumbra had a return on equity of 9.73% and a net margin of 1.17%.

Several other research firms also recently commented on PEN. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a research note on Wednesday. BTIG Research raised their price objective on Penumbra from $232.00 to $270.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. JPMorgan Chase & Co. raised their price objective on Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday. Citigroup raised their price objective on Penumbra from $220.00 to $245.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 11th. Finally, Morgan Stanley lifted their target price on Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $292.64.

Penumbra Stock Down 0.3 %

NYSE PEN opened at $302.82 on Thursday. The stock’s 50-day moving average price is $257.15 and its 200-day moving average price is $226.51. The company has a quick ratio of 3.25, a current ratio of 5.82 and a debt-to-equity ratio of 0.02. Penumbra has a 52 week low of $148.00 and a 52 week high of $310.00. The company has a market capitalization of $11.62 billion, a P/E ratio of 890.64, a price-to-earnings-growth ratio of 1.99 and a beta of 0.53.

Insiders Place Their Bets

In other news, CEO Adam Elsesser sold 15,000 shares of Penumbra stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $242.96, for a total value of $3,644,400.00. Following the completion of the transaction, the chief executive officer now owns 837,582 shares in the company, valued at approximately $203,498,922.72. The trade was a 1.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Harpreet Grewal sold 167 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $241.28, for a total value of $40,293.76. Following the transaction, the director now owns 8,530 shares of the company’s stock, valued at approximately $2,058,118.40. The trade was a 1.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,219 shares of company stock valued at $4,426,439 in the last quarter. 5.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Penumbra

Several hedge funds have recently made changes to their positions in PEN. True Wealth Design LLC bought a new position in shares of Penumbra in the 3rd quarter worth $26,000. UMB Bank n.a. grew its stake in Penumbra by 57.4% during the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after purchasing an additional 70 shares during the last quarter. Hurley Capital LLC purchased a new stake in Penumbra during the 4th quarter valued at about $56,000. Huntington National Bank grew its stake in Penumbra by 138.7% during the 4th quarter. Huntington National Bank now owns 265 shares of the company’s stock valued at $63,000 after purchasing an additional 154 shares during the last quarter. Finally, Mather Group LLC. boosted its stake in shares of Penumbra by 208.0% in the fourth quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after buying an additional 208 shares during the last quarter. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.